Anticancer Treatments and Cardiotoxicity

Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.

This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.

Autorentext
Patricio Lancellotti is head of the intensive care cardiology unit at the University of Liège Hospital Center and Professor of Clinical Medicine at the University of Liège. His research, conducted at Professor Luc Piérard's department of cardiology, has led to significant progress in the care of patients suffering from functional mitral insufficiency, a pathology often underestimated clinically yet weighing heavily on the prognosis. He has 300 peer-reviewed articles and an H-index = 40. José Luis Zamorano is Professor of Medicine and Head of Cardiology at the University Complutense in Madrid and Director of the Cardiovascular Institute at the University Clinic San Carlos, Madrid. His key research interests include ischemic heart disease, cardiovascular risk factors and imaging modalities. Professor Zamorano is President Elect of the European Association of Echocardiography (EAE) and President of the Working Group on Non-invasive Diagnostic Imaging of the Spanish Society of Cardiology. He serves on numerous Editorial Boards, including the European Journal of Echocardiography, the American Society of Echocardiography and the European Heart Journal. He has authored over 400 articles for peer-reviewed journals and has an H-index = 57.Maurizio Galderisi, is Associate Professor of Cardiology and Clinical Director at Federico II University Hospital in Italy. His research interests include cardiac function, heart failure, arterial hypertension, tissue Doppler and strain rate imaging, coronary flow reserve. He has served as editor of one book and author of 10 chapters in various cardiologic books. He is the author or co-author of 250 articles on international peer-reviewed indexed journals, with an H-index = 38. He has been an invited speaker at more than 70 major national and international meetings and holds scientific association membership with Società Italiana di Cardiologia (SIC), Società Italiana di Ecografia Cardiovascolare (SIEC), European Association of Echocardiography (EAE), and the American Society of Echocardiography (ASE).

Inhalt
Section I: General Considerations
1. Epidemiology and Trend of Prognosis in Cancer Patients

2. Categories of Anticancer Treatments
3. Classification by Mechanisms of Cardiotoxicity
4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?

5. The Impact of Radiotherapy

   Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart
   6. Lessons From Preclinical Models

6. Genetic and Epigenetic Risk Factors
7. Changes of Myocardial Structure and Function
8. Alteration of Heart Valves
9. Pericardial Damage
10. Effects of Radiotherapy on Vessels and Coronary Arteries

11. Cardiac Conduction Disturbances

    Section III: Cardiovascular Complications of Cancer Treatments
    13. Cardiac Rhythm Disturbances

12. Acute and Chronic Heart Failure
13. Coronary Artery Disease
14. Pericardial Effusion and Pericarditis
15. Radiation-Induced Carotid Atherosclerosis
16. Valvular Heart Disease

17. Atrial Fibrillation and Stroke in Cancer Patients

    Section IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients
    20. The Role of Echocardiography

18. The Role of Cardiovascular Magnetic Resonance (CMR)

19. Nuclear Medicine Imaging and Cardiotoxicity

    Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity
    23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography

20. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers
21. Screening and Comprehensive Follow-Up Evaluation

22. Preoperative Assessment for Noncardiac Surgery

    Section VI: Cardiotoxicity in Childhood
    27. Cardiotoxicity of Childhood Cancer Treatments

    Section VII: Management of Anticancer Drugs Related Cardiotoxicity
    28. Nonpharmacologic Therapy

23. Beta-Blockers
24. Angiotensin-Converting Enzyme Inhibition
25. Diuretics
26. Antiarrhythmic Drugs
27. Anticoagulation in Cancer Patients
28. New Drugs: The Beneficial Effects of Ranolazine
29. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients
30. Focus on the Patient With Known Cardiac Disease

31. Multidisciplinary Approach to Cardiac Disease in Cancer Patients

    Section VIII: Future Research Priorities
    38. Pharmacogenomics Screening

32. Cardiac Monitoring During Clinical Trials
33. Preventive Therapy
34. Cardiotoxicity: Future Research Directions